Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery

被引:46
作者
Doughty, Diane V. [1 ]
Clawson, Corbin Z. [1 ]
Lambert, William [1 ]
Subramony, J. Anand [1 ]
机构
[1] MedImmune LLC, Biopharmaceut Dev, Drug Delivery & Device Dev, Gaithersburg, MD 20878 USA
关键词
skin; injectables; injectors; physiological model; biocompatibility; monoclonal antibody; subcutaneous; parenteral; device; pain; IMMUNOGLOBULIN REPLACEMENT; MONOCLONAL-ANTIBODY; PREFILLED SYRINGE; PAIN; THERAPY; PHARMACOKINETICS; TRASTUZUMAB; CHALLENGES; TOXICOLOGY; DURATION;
D O I
10.1016/j.xphs.2016.04.009
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Subcutaneous injection allows for self-administration of monoclonal antibodies using prefilled syringes, autoinjectors, and on-body injector devices. However, subcutaneous injections are typically limited to 1 mL due to concerns of injection pain from volume, viscosity, and formulation characteristics. Back pressure can serve as an indicator for changes in subcutaneous mechanical properties leading to pain during injection. The purpose of this study was to investigate subcutaneous pressures and injection site reactions as a function of injection volume and flow rate. A pressure sensor in the fluid path recorded subcutaneous pressures in the abdomen of Yorkshire swine. The subcutaneous tissue accommodates large-volume injections and with little back pressure as long as low flow rates are used. A 1 mL injection in 10 seconds (360 mL/h flow rate) generated a pressure of 24.0 +/- 3.4 kPa, whereas 10 mL delivered in 10 minutes (60 mL/h flow rate) generated a pressure of 7.4 +/- 7.8 kPa. After the injection, the pressure decays to 0 over several seconds. The subcutaneous pressures and mechanical strain increased with increasing flow rate but not increasing dose volume. These data are useful for the design of injection devices to mitigate back pressure and pain during subcutaneous large-volume injection. (C) 2016 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:2105 / 2113
页数:9
相关论文
共 45 条
[1]   The mechanical properties of human adipose tissues and their relationships to the structure and composition of the extracellular matrix [J].
Alkhouli, Nadia ;
Mansfield, Jessica ;
Green, Ellen ;
Bell, James ;
Knight, Beatrice ;
Liversedge, Neil ;
Tham, Ji Chung ;
Welbourn, Richard ;
Shore, Angela C. ;
Kos, Katarina ;
Winlove, C. Peter .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2013, 305 (12) :E1427-E1435
[2]   Recombinant Human Hyaluronidase-Enabled Subcutaneous Pediatric Rehydration [J].
Allen, Coburn H. ;
Etzwiler, Lisa S. ;
Miller, Melissa K. ;
Maher, George ;
Mace, Sharon ;
Hostetler, Mark A. ;
Smith, Sharon R. ;
Reinhardt, Neil ;
Hahn, Barry ;
Harb, George .
PEDIATRICS, 2009, 124 (05) :E858-E867
[3]   Measuring Tissue Back-Pressure - In Vivo Injection Forces During Subcutaneous Injection [J].
Allmendinger, Andrea ;
Mueller, Robert ;
Schwarb, Edward ;
Chipperfield, Mark ;
Huwyler, Joerg ;
Mahler, Hanns-Christian ;
Fischer, Stefan .
PHARMACEUTICAL RESEARCH, 2015, 32 (07) :2229-2240
[4]   Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions [J].
Bayas, Antonios ;
Gold, Ralf ;
Naumann, Markus .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 324 (1-2) :53-56
[5]   IMMUNOGLOBULIN REPLACEMENT THERAPY BY SLOW SUBCUTANEOUS INFUSION [J].
BERGER, M ;
CUPPS, TR ;
FAUCI, AS .
ANNALS OF INTERNAL MEDICINE, 1980, 93 (01) :55-56
[6]   Educational session as a tool to increase patient satisfaction of switching etanercept from the prefilled syringe to the autoinjection pen [J].
Borras-Blasco, Joaquin ;
Gracia-Perez, Antonio ;
Dolores-Elvira Castera, M. ;
Dolores Rosique-Robles, J. ;
Abad, Javier .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (08) :1103-1108
[7]   Acceptability of switching adalimumab from a prefilled syringe to an autoiniection pen [J].
Borras-Blasco, Joaquin ;
Gracia-Perez, Antonio ;
Dolores Rosique-Robles, J. ;
Dolores-Elvira Castera, M. ;
Javier Abad, F. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (03) :301-307
[8]   Current perspectives on pain upon injection of drugs [J].
Brazeau, GA ;
Cooper, B ;
Svetic, KA ;
Smith, CL ;
Gupta, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (06) :667-677
[9]   Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901 [J].
Byrd, John C. ;
Peterson, Bercedis L. ;
Rai, Kanti R. ;
Hurd, David ;
Hohl, Raymond ;
Perry, Michael C. ;
Gockerman, Jon ;
Nattam, Sreenivasa ;
Larson, Richard A. .
LEUKEMIA & LYMPHOMA, 2009, 50 (10) :1589-1596
[10]   GOLIMUMAB: A NOVEL ANTI-INF-α HUMAN MONOCLONAL ANTIBODY FOR RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS [J].
Campas-Moya, Clara .
DRUGS OF TODAY, 2010, 46 (01) :13-22